Filter
1353
Text search:
drug
approval
Featured
95
396
Language
1332
16
13
9
6
6
5
4
3
1
1
1
1
1
Document type
766
255
179
64
39
25
17
4
3
1
Countries / Regions
91
47
42
39
37
34
32
32
28
27
25
24
24
23
22
21
21
20
18
14
14
13
13
12
12
12
11
9
8
8
8
7
6
6
5
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
189
64
59
37
22
21
19
16
12
12
11
11
10
9
9
9
8
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
341
879
123
8
1
1
Category
613
105
41
38
32
31
13
Toolboxes
130
113
101
72
72
64
55
25
24
22
18
18
17
16
12
12
11
10
9
7
5
4
4
1
1
This report examines how clinical trials contribute to environmental impacts and outlines key considerations for integrating environmental sustainability into trial design, conduct and oversight. It explores the carbon footprint and resource use associated with clinical research activities – inclu
...
ding site operations, participant travel, supply chains, data management and waste – and highlights how these impacts intersect with climate change risks to health systems and research infrastructure.
more
Guide to revision of national pandemic influenza preparedness plans - Lessons learned from the 2009 A(H1N1) pandemic
Brown C., Ciotti M., Hegermann-Lindencrone M., et al
European Centre for Disease Prevention and Control (ECDC), WHO Regional Office for Europe
(2017)
C_WHO
The document “Guide to revision of national pandemic influenza preparedness plans – Lessons learned from the 2009 A(H1N1) pandemic” provides guidance for countries on how to improve and update their national pandemic preparedness plans. It is based on lessons learned from the 2009 influenza pa
...
ndemic and aims to help governments strengthen their readiness for future pandemics. The report outlines key components of effective pandemic planning, including risk assessment, coordination between sectors, communication strategies, healthcare system preparedness, vaccination and antiviral strategies, and business continuity planning. It also emphasizes the importance of international cooperation and flexible planning that can adapt to different pandemic scenarios. Overall, the guide serves as a framework to support countries in developing stronger, more coordinated responses to future influenza pandemics.
more
The document provides guidance from the CDC on conducting an Operational Readiness Review (ORR) within the Public Health Emergency Preparedness (PHEP) cooperative agreement. It outlines the purpose, structure, and evaluation criteria used to assess whether public health systems are prepared to respo
...
nd effectively to emergencies. The guidance describes required capabilities, review processes, and documentation expectations, helping jurisdictions demonstrate their readiness and identify areas for improvement in emergency preparedness and response.
more
BMC Public Health (2025) 25:3774 https://doi.org/10.1186/s12889-025-24555-6. The study results provide useful insights on how climate change influences malaria in African countries, and reiterates the need for a greater engagement of policymakers and social partners, in intensifying the action neede
...
d to fight the transmission of malaria in Sub-Sahara Africa
more
As countries presented their epidemiological and programmatic situations, and WHO summarized the global status of HAT, the central message was one of satisfaction with the remarkable progress towards elimination. A historically low number of cases was reported, despite maintaining high levels of act
...
ive and passive screening in all accessible at-risk areas. In addition, 10 countries have been officially validated for the elimination of HAT as a public health problem.
Time was also devoted to reviewing progress and challenges in the areas of diagnostics, therapeutics and vector control interventions.
more
A Global Access Framework for Country-Led.
ResponsesThis 2030 Prevention access framework focuses on one of those top-line targets, which covers primary prevention and requires that 90% of people in need of HIV prevention are using effective prevention options by 2030. This target is disaggregated
...
into 15 second-line prevention targets for specific populations and programmes.
The 2030 Prevention Access Framework presents in greater detail the milestones and actions for achieving these targets––all of which are grounded in the three priorities of the Global AIDS Strategy: country-led, resilient and sustainable HIV responses; people-focused services, and community leadership
more
Indicators and questions to monitor progress towards the Global AIDS Strategy 2026-2031 targets
This report developed by UNAIDS and the United for Global Mental Health reviews and maps Global Fund investments in priority HIV and TB comorbidities in Grant Cycle 7 (GC7), including key non-communicable diseases (NCDs), cervical, anorectal and other cancers, and mental health and substance use co
...
nditions. It highlights how countries prioritize and are integrating health services and other interventions with HIV and TB programmes to advance person-centered approaches and to sustain HIV and TB responses. Analyzing approved grants from 103 countries, the report finds strong demand for integrated approaches, with 97% of countries prioritizing at least one comorbidity.
more
2nd Generation HIV Surveillance in Pakistan, Round 5
The Overall objective of this mapping study was to update population size estimates of selected key populations (PWID, FSWs, MSM & TGs) to create evidence for developing action plans for HIV prevention interventions in Pakistan. A total numbe ... r of 23 cities/towns were selected for Mapping. This included 13 cities in Punjab province, 6 in Sindh Province and 2 cities each in KPK and Baluchistan provinces.
large file: 70,5 MB The preview/download includes only the pages 1 to 23. more
The Overall objective of this mapping study was to update population size estimates of selected key populations (PWID, FSWs, MSM & TGs) to create evidence for developing action plans for HIV prevention interventions in Pakistan. A total numbe ... r of 23 cities/towns were selected for Mapping. This included 13 cities in Punjab province, 6 in Sindh Province and 2 cities each in KPK and Baluchistan provinces.
large file: 70,5 MB The preview/download includes only the pages 1 to 23. more
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,
...
which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
